Xechem’s (OTCBB: XKEM) Orphan Drug Status Approved for New Sickle Cell Drug
Recently, the EU approved "Orphan Drug Status" for Xechem International's sickle cell drug dubbed Niprisan, a phytopharmaceutical product that has shown efficacy in the treatment of Sickle Cell Disease. The designation covers all 25 member countries that comprise the European Union. A similar Orphan Drug Status was granted to Xechem by the U.S. Food and Drug Administration. Dr. Ramesh Pandey, Xechem's Chairman & CEO said, "Obtaining Orphan Drug status for our Sickle Cell Disease product in both the European Union and the United States brings to Xechem substantial advantages and incentives which will help facilitate approval of the drug and…